Dry eye disease (DED) is a prevalent and multifactorial condition affecting a significant proportion of the global population (~30%), characterized by ocular discomfort, visual disturbances, and chronic inflammation. Cyclosporine A (CyA), a potent immunomodulatory agent, is widely used for DED treatment, but its clinical application is limited by poor water solubility, low ocular bioavailability, rapid clearance, and irritation associated with conventional oil-based formulations. To address these challenges, we developed hyaluronic acid-conjugated CyA (HA-CyA) nanomicelles to enhance ocular retention, targeted cellular uptake, and therapeutic efficacy. HA-CyA was synthesized via a click reaction between propargylated hyaluronic acid and azidated CyA, forming self-assembled nanomicelles in an aqueous solution. The nanomicelles were characterized for particle size, zeta potential, morphology, critical micelle concentration, drug loading, and enzymatic-triggered release. In vitro studies demonstrated high biocompatibility, minimal irritancy, and efficient uptake in human corneal epithelial cells, mediated in part by HA-CD44 interactions. In vivo safety evaluation in rabbits confirmed the absence of ocular toxicity, epithelial defects, or apoptosis. Therapeutic efficacy in atropine-induced DED rabbit models showed that HA-CyA nanomicelles significantly improved tear production, tear film stability, and corneal epithelial integrity, while reducing inflammatory cytokines (TNF-α, IL-1β) compared with commercially available 0.05% CyA eye drops (Restasis®) and 0.15% HA artificial tears (Artipic Advanced®). These findings highlight HA-CyA nanomicelles as a novel, targeted ocular drug delivery platform with prolonged retention, reduced irritation, and effective anti-inflammatory activity for DED management.